ACS Cancer Research Program 
More in this category
- ACS Clinical Research Program sessions at Clinical Congress 2019: A recap
- Modified FOLFIRINOX is superior to gemcitabine as adjuvant therapy for resected pancreatic cancer: The PRODIGE 24/CCTG PA6 Trial
- ALCHEMIST trial has potential to improve outcomes after lung cancer resection
- Could axillary reverse mapping be useful in reducing surgical comorbidities?
- Evolution in the management of desmoid tumors: Challenging the role of upfront surgical resection
- Putting the needle before the knife: Minimally invasive approaches to diagnostic lymph node biopsy in melanoma
- Gastric cancer: Recent updates in surgical and multimodality therapy
- Organ preservation in rectal adenocarcinoma: The OPRA Trial
- Opportunities at Clinical Congress 2019 to increase surgeon participation in clinical research
- Defining the optimal treatment of locally advanced gastric cancer
- Preoperative smoking intervention techniques improve outcomes for lung cancer patients
- Atezolizumab in the adjuvant treatment of stage III colon cancer: Can PD-L1 inhibition improve survival?
- Cytoreduction with or without HIPEC: Where do we go from here?
- Robotic surgery for hepatic neoplasms: Where does it fit in the minimally invasive surgery landscape?
- Surveillance testing for colorectal cancer: New evidence supports a change in guidelines
- Colorectal cancer in adults younger than 50 years old
- The evolving clinical management of sentinel node-positive melanoma: The impact of MSLT-II on clinical practice
- Liquid biopsies in cancer clinical trials
- Geriatric assessment and frailty in older cancer patients
- Immunotherapy in solid tumors